SCHEMBL9902866

SCHEMBL9902866

CNCC(N)c1cccc(Cl)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 8/20 0.49
SLC6A2 P23975 7/20 0.49
PNMT P11086 1/20 0.44
GBA1 P04062 1/20 0.44
TAAR1 Q96RJ0 1/20 0.43
AOC3 Q16853 1/20 0.43
AURKA O14965 1/20 0.42
RPS6KB1 P23443 1/20 0.42
SLC6A3 Q01959 5/20 0.41
ADRB2 P07550 2/20 0.41
ADRB1 P08588 2/20 0.41
ADRB3 P13945 2/20 0.41
HIF1A Q16665 2/20 0.41
HTR1A P08908 1/20 0.41
ADRA2A P08913 1/20 0.41
TSHR P16473 1/20 0.41
ADRA2B P18089 1/20 0.41
ADRA2C P18825 1/20 0.41
NFKB1 P19838 1/20 0.41
DRD1 P21728 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16690960 1.00 SLC6A4 (0.49) SLC6A4SLC6A2PNMTGBA1TAAR1
SCHEMBL1974847 0.79 OPRM1 (0.50) SLC6A4PNMTGBA1AOC3
SCHEMBL5101972 0.79 OPRM1 (0.50) SLC6A4PNMTGBA1AOC3
SCHEMBL8037342 0.79 OPRM1 (0.50) SLC6A4PNMTGBA1AOC3
SCHEMBL11075225 0.79 SLC6A4 (0.47) SLC6A4SLC6A2PNMTTAAR1AOC3
SCHEMBL5572699 0.79 SLC6A2 (0.40) SLC6A4SLC6A2PNMTGBA1AOC3
SCHEMBL16679636 0.79 ADRB1 (0.67) SLC6A4SLC6A2TAAR1SLC6A3ADRB2
SCHEMBL9903509 0.79 SLC6A2 (0.49) SLC6A4SLC6A2GBA1TAAR1AOC3
SCHEMBL3702012 0.79 ADRB1 (0.67) SLC6A4SLC6A2TAAR1SLC6A3ADRB2
Hydrochloric Acid SCHEMBL23527440 0.78 OPRM1 (0.49) PNMTGBA1AOC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2462141-B1 NOVEL AZAHETEROCYCLIC COMPOUNDS MERCK PATENT GMBH (DE) 2017-09-27 EP claimed
US-9023847-B2 Azaheterocyclic compounds MERCK PATENT GMBH (DE) 2015-05-05 US claimed
US-20120277228-A1 Novel Azaheterocyclic Compounds MERCK PATENT GMBH (DE) 2012-11-01 US claimed
EP-2462141-A1 NOVEL AZAHETEROCYCLIC COMPOUNDS Merck Patent GmbH (DE) 2012-06-13 EP claimed
US-9023847-B2 Azaheterocyclic compounds MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-20120277228-A1 Novel Azaheterocyclic Compounds MERCK PATENT GMBH (DE) 2012-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120277228-A1 Novel Azaheterocyclic Compounds PCNA, MCL1, MYC SLC6A4 4881/4885SLC6A2 4867/4885PNMT 4344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.